Skip to main content
Search
Newsletters
Watchlist
Latest in
TSX Today:
ENB-T
-2.28%
BB-T
+11.82%
SU-T
-1.31%
CVE-T
-1.36%
MFC-T
+1.02%
HBM-T
+14.06%
RY-T
-0.45%
Search stocks, ETFs and Commodities
Instrument Name
Organon & Co.
Instrument Symbol
(OGN-N)
Instrument Exchange
NYSE
Add to Watchlist
Create Alerts
USD
Today's Change
Real-Time
Last Update
Last Sale
Cboe BZX Real-Time
USD
Pre Market
Change
Pre Market
Last Update
Pre Market
Price
Volume
Summary
Charts
Profile
Financials
Statistics
Dividends
Price History
Analyst Estimates
Insiders
Organon & Co.
30 Hudson Street FL 33
Jersey City NJ 07302 USA
P:
551-430-6900
http://www.organon.com
Sectors & Indices
Sector
Industry
Employees
SIC-2834 Pharmaceutical Preparations
Medical Services
Indices S&P 600
Indices Russell 1000
Indices Russell 3000
Profile
Organon is a healthcare company. It focuses on the health of women throughout their lives. Organon is based in JERSEY CITY, N.J.
Key Executives
Name
Title
Matthew M. Walsh
CFO/Executive VP
Juan Camilo Arjona Ferreira
Chief Medical Officer/Executive VP/Other Corporate Officer
Rachel A. Stahler
Chief Information Officer/Executive VP
Kevin Ali
CEO/Director
Aaron Falcione
Executive VP/Other Executive Officer
Susanne Fiedler
Executive VP/Other Executive Officer
Joseph T. Morrissey
Executive VP/Other Corporate Officer
Vittorio Nisita
Executive VP/Other Corporate Officer
Kirke Weaver
Executive VP/General Counsel/Secretary
More from The Globe
Premarket: Futures jump after U.S. consumer price data
3 hours ago
Chevron tops Tesla as most-shorted stock in April, says Hazeltree
Yesterday
The close: Nasdaq at record high after Fed chair’s comments but TSX dips for third day
Yesterday
The close: S&P 500, TSX slip as investors await inflation data; meme rally reignites
May 13, 2024
Shopify executive earned US$76-million in 2023, far outpacing CEO’s compensation
May 12, 2024
Advantage Energy director buys as stock rallies
Ted Dixon
May 10, 2024
The close: S&P 500 higher but TSX slips as traders await key U.S. inflation data
May 10, 2024
How pro money managers are balancing exposure to Canadian and U.S. stocks
Rob Carrick
May 6, 2024